<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="373283">
  <stage>Registered</stage>
  <submitdate>10/07/2017</submitdate>
  <approvaldate>3/08/2017</approvaldate>
  <actrnumber>ACTRN12617001138370</actrnumber>
  <trial_identification>
    <studytitle>Analgesic efficacy of local anesthetics articaine and bupivacaine after impacted third molar extraction
</studytitle>
    <scientifictitle>Double-blind, randomized controlled trial on analgesic efficacy of local anesthetics articaine and bupivacaine after impacted third molar extraction
</scientifictitle>
    <utrn>U1111-1198-9779</utrn>
    <trialacronym />
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>third molar surgery</healthcondition>
    <healthcondition>postoperative pain</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Surgical extraction of lower third molars under local anesthesia with  bupivacaine were performed. 0.5% bupivacaine with 1:200,000 epinephrine were administered subcutaneously before the surgical extraction. Between 2 and 4 carpules of bupivacaine were administered (2 ml per carpule). The number of carpules depended on the quaility of the intraoperative anesthesia achieved (If patient felt discomfort/pain and additional carpule were administered and recorded in the history)

</interventions>
    <comparator>Active control (4% articaine with 1:100,000 epinephrine). Surgical extraction of lower third molars under local anesthesia with 4% articaine with 1:100,000 epinephrine administered subcutaneously before the surgical extraction. Between 2 and 4 carpules of articaine were administered. The number of carpules depended on the quaility of the intraoperative anesthesia achieved (If patient felt discomfort/pain and additional carpule were administered and recorded in the history)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Postoperative pain intentsity.
During the 48-h postoperative period, each patient completed a data collection form with the following outcome variables: postoperative pain intensity at 2, 4, 6, 8, 10, 12, 24, and 48 h, using a horizontal 100-mm visual analogue scale (VAS) with no pain and worst pain imaginable as end-points</outcome>
      <timepoint>At 2, 4, 6, 8, 10, 12, 24, and 48 h post-surgery
</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Consumption of rescue medication.
Each patient completed a data collection form with their need for rescue analgesia with 1 g paracetamol (yes/no) and its timing.</outcome>
      <timepoint>At 2, 4, 6, 8, 10, 12, 24, and 48 h post-surgery
</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The quality of intraoperative anesthesia.
It was classified as no discomfort during surgery, discomfort/pain not requiring additional anesthesia; or discomfort/pain requiring additional anesthesia.
</outcome>
      <timepoint>During the surgery</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All participants must be undergoning impacted third molar extraction. Caucasian participants, absence of general medical disorders, no allergy to the study medication or related drugs, no receipt of medication with analgesic or anti-inflammatory properties less than 24 h before the surgery, absence of preoperative inflammation and pain at the surgical site, and absence of clinical or radiographic evidence of active oral disease</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>30</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Age under 18 yrs, renal failure, pregnancy or breast-feeding, allergy to the study medication or related drugs, immunocompromised status, psychological disorder, epilepsy, receipt of medication with analgesic or anti-inflammatory properties less than 24 h before the surgery, preoperative inflammation and pain at the surgical site, and clinical or radiographic evidence of active oral disease. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Surgeons and patients were blinded by labeling the articaine and bupivacaine carpules with the numbers 1 and 2, respectively</concealment>
    <sequence>A computer-generated random sequence was used to allocate participants</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>The sample size was calculated using the Sample Sizer Release statistical program (Microsoft Office Excel 2011), with an alpha value of 0.05, statistical power of 80 %, and assumed loss to the follow-up of 15 %. According to this calculation, the number of patients required per group was 24, and we finally included 25 patients in each group.
SPSS v 20.0 software (SPSS Inc., Chicago, IL) was used for data analysis. Variable normality was verified with the Anderson-Darling test. The association between types of anesthesia and different variables was analyzed using the Fisher or Chi-square test.
Bupivacaine and articaine group data were compared at each time-point using the Mann-Whitney U test. The proportions of individuals requiring rescue medication in each group were compared with a proportion test based on binomial distribution. P&lt; 0.05 was considered significant in all tests.
</statisticalmethods>
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate>31/03/2016</actualenddate>
    <samplesize>50</samplesize>
    <actualsamplesize>50</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>30/04/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Granada</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Master of Oral Surgery and Implant Dentistry, University of Granada, Spain</primarysponsorname>
    <primarysponsoraddress>Colegio Maximo s/n, Campus de Cartuja, Granada. 18071</primarysponsoraddress>
    <primarysponsorcountry>Spain</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Master of Oral Surgery and Implant Dentistry, University of Granada, Spain</fundingname>
      <fundingaddress>Colegio Maximo s/n, Campus de Cartuja, Granada. 18071</fundingaddress>
      <fundingcountry>Spain</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Departmento of Stomatology, School of Dentistry, University of Granada</sponsorname>
      <sponsoraddress>Colegio Maximo s/n, Campus de Cartuja, Granada. 18071</sponsoraddress>
      <sponsorcountry>Spain</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Objectives The objective of this randomized controlled clinical trial (RCT) was to compare the effect of bupivacaine and articaine at habitual doses on pain intensity and the need for analgesics after lower third molar extraction.
Materials and Methods The final study sample comprised 50 Caucasian volunteers (26 males and 24 females; age range, 18-30 yrs) undergoing scheduled surgical extraction of impacted lower third molar. A computer-generated random sequence was used to allocate participants to the articaine (4%) or bupivacaine (0.5%) group. Measurements were conducted of postoperative pain intensity, using a visual analogue scale (VAS), rescue medication requirement and its timing, and the quality of intraoperative anesthesia.
Results VAS-measured pain intensity was significantly higher (p&lt;0.05) in the articaine group than in the bupivacaine group at all time-points except for 8 h post-surgery (p = 0.052). Rescue medication was required by 13 (52%) patients in the articaine group and 8 (32%) patients in the bupivacaine group, although the difference did not reach statistical significance (p=0.252). The groups did not significantly differ (p=0.391) in the quality of the intraoperative anesthesia.
Conclusions Bupivacaine is a valid alternative to articaine in third molar surgery and may offer residual anesthesia as a means of reducing postoperative pain. However, further well-designed RCTs are required in larger study populations to verify the effectiveness of bupivacaine to achieve residual analgesia after oral surgery.
Clinical relevance. These findings suggest that bupivacaine may be useful as coadjuvant to control acute postoperative pain. 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics committee of the University of Granada</ethicname>
      <ethicaddress>Colegio MÃ¡ximo s/n, Campus de Cartuja, Granada. 18071</ethicaddress>
      <ethicapprovaldate>27/02/2014</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/01/2014</ethicsubmitdate>
      <ethiccountry>Spain</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Francisco Javier Manzano-Moreno</name>
      <address>Department of Stmatology, School of Dentistry, University of Granada.

Campus de Cartuja s/n,  18071, Granada.</address>
      <phone>+34651606228</phone>
      <fax />
      <email>fjmanza@ugr.es</email>
      <country>Spain</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Francisco Javier Manzano-Moreno</name>
      <address>Department of Stmatology, School of Dentistry. University of Granada.
Campus de Cartuja s/n. 18071. Granada</address>
      <phone>+34651606228</phone>
      <fax />
      <email>fjmanza@ugr.es</email>
      <country>Spain</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Francisco Javier Manzano-Moreno</name>
      <address>Department of Stmatology, School of Dentistry. University of Granada.
Campus de Cartuja s/n. 18071. Granada</address>
      <phone>+34651606228</phone>
      <fax />
      <email>fjmanza@ugr.es</email>
      <country>Spain</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Francisco Javier Manzano-Moreno</name>
      <address>Department of Stmatology, School of Dentistry, Campus de Cartuja s/n. 18071. Granada</address>
      <phone>+34651606228</phone>
      <fax />
      <email>fjmanza@ugr.es</email>
      <country>Spain</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>